skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration
3,000
clients
300
specialists
175
covered countries
248,000 
trials tracked daily

Analysis, insight and consultancy

Our analysis, insight and consultancy services span drug, device, company, clinical trial and market intelligence. All our services are delivered by an authoritative team of industry experts in key markets around the globe. And because our approach is interconnected, our analysts can give a broader perspective, identifying disruptive events, and in turn, helping you spot opportunities and mitigate risk.

Our specialities

business Intelligence sales forecasts pharma intelligence

Business intelligence

We’re the world’s leading provider of drug, device, company, clinical trial and market intelligence in the competitive pharma and medtech markets.

news and insight analyst page expertise in all areas pharma intelligence

News and insight

We provide unrivalled and daily-updated global insight, drawn from extensive authoritative data sets and enriched by human validation.

data and analysis indepth company profiles pharma intelligence

Data and analysis

Our premium quality data is drawn from 42,000 companies, 248,000 clinical trials in 175 countries and 65,000 drugs for 1,400 diseases.

consultancies pharma intelligence

Consultancy

Our bespoke clinical, commercial and market access solutions are designed to help you make smarter decisions that bring a better return on investment.

Global industry experts

Global industry experts

Working in an interconnected global network, our 65 journalists and over 300 in-house analysts supply comprehensive analysis and reports.

Trusted partnerships

Trusted partnerships

We’re the trusted partner of more than 3,000 companies including the top 50 pharma firms and top 10 contract research organizations.

ask the analyst pharma intelligence

Gold-standard service

Our customer services team will support you every step of the way so that our insight, intelligence and bespoke solutions match your needs.

Solution to suit needs

Tailor-made solutions

From single reports and data downloads to enterprise subscriptions to custom consultancy, we can base our precise solutions round your exact needs.

 Meet the team

Analyst

Benjamin Graham

​Drug Analyst

London , UK

BenjaminGraham

Benjamin Specialises in

  • InfectiousDiseases

+ 3 years experience

Analyst

Armando Uribe

Analytics Analyst

San Diego , USA

ArmandoUribe

Armando Specialises in

  • DealsandFinancing
  • CommercialStrategy

+ 5 years experience

Analyst

David Dahan

Scientific Analyst

San Diego , USA

David Dahan Pharmaintelligence

David Specialises in

  • InfectiousDiseases
  • ClinicalTrials

+ 20 years experience

How we've helped other businesses

"RxScorecard™ lets a biopharma company anticipate the most important factors impacting the clinical & economic value of pipeline and marketed drugs -- and then helps identify the necessary changes to the clinical development and commercial program to maximize that value for all stakeholders, especially including payers. It's a required, straightforward, objective strategic tool that allows us to quickly and effectively adapt to a rapidly changing and much more challenging market access environment."

​Ammar Qadan ​Global Value/Market Access Lead Oncology Portfolio & Global Commercial Lead Oncology Biomarkers Halozyme Therapeutics, Inc.

"RxScorecard™ provides a comprehensive, multi-pronged rubric assisting us in decision-making as we begin to move from a volume to value drug evaluation methodology."

​Chronis H. Manolis, RPh ​Vice President, Pharmacy UPMC Health Plan

“With pharmacy costs increasing so quickly, there is increasing pressure for P&T and Technology Assessment Committees to consider the value as well as the clinical efficacy of the drugs under evaluation. By providing an objective framework for assessing value, RxScorecard™ fills a gap in the existing toolkit available to health plans. And with greater discussion around narrower formularies, RxScorecard™ becomes even more important.”

​Michael S. Sherman, MD, MBA ​Senior Vice President and Chief Medical Officer Harvard Pilgrim Health Care

"We at GSK believe that it’s critical for the pharmaceutical industry to produce drugs that deliver value for patients, providers and payers. We have found RxScorecard™ to be an insightful framework for assessing and comparing the value of drugs, both marketed and developmental assets. The perspective it provides supports improved customer-focused development and commercialization, and we and our customers can benefit from its use.”

​Jack Bailey ​President GlaxoSmithKline U.S.